Michel Rudolphie - Mydecine Innovations Pres Operations
| MYCOF Stock | USD 0 0 28.00% |
Insider
Michel Rudolphie is Pres Operations of Mydecine Innovations Group
| Phone | 720 277 9879 |
| Web | https://www.mydecine.com |
Mydecine Innovations Management Efficiency
The company has return on total asset (ROA) of (1.7615) % which means that it has lost $1.7615 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (12.244) %, meaning that it generated substantial loss on money invested by shareholders. Mydecine Innovations' management efficiency ratios could be used to measure how well Mydecine Innovations manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | INSIDER Age | ||
| Alejandro Patio | Genomma Lab Internacional | N/A | |
| Daniel Neria | Genomma Lab Internacional | N/A | |
| Jorge Valderrama | Genomma Lab Internacional | N/A | |
| Mximo Juda | Genomma Lab Internacional | N/A | |
| L Porres | Genomma Lab Internacional | N/A | |
| Engineer Galland | Genomma Lab Internacional | N/A | |
| Marianne Velasco | Genomma Lab Internacional | N/A | |
| Juan Sparvieri | Genomma Lab Internacional | N/A | |
| Efran Crdova | Genomma Lab Internacional | N/A | |
Management Performance
| Return On Equity | -12.24 | |||
| Return On Asset | -1.76 |
Mydecine Innovations Leadership Team
Elected by the shareholders, the Mydecine Innovations' board of directors comprises two types of representatives: Mydecine Innovations inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mydecine. The board's role is to monitor Mydecine Innovations' management team and ensure that shareholders' interests are well served. Mydecine Innovations' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mydecine Innovations' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sanford Stein, Gen Officer | ||
| Damon Michaels, CoFounder COO | ||
| Robert MA, Chief CoFounder | ||
| William Cook, Interim Inc | ||
| Morgan Kervitsky, Director Marketing | ||
| Michel Rudolphie, Pres Operations | ||
| David Bartch, CEO, CoFounder | ||
| MD FRCPC, Chief Officer |
Mydecine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Mydecine Innovations a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -12.24 | |||
| Return On Asset | -1.76 | |||
| Current Valuation | 8.64 M | |||
| Shares Outstanding | 13.01 M | |||
| Shares Owned By Insiders | 8.71 % | |||
| Price To Book | 23.41 X | |||
| Price To Sales | 677.59 X | |||
| Revenue | 7.49 K | |||
| Gross Profit | 7.49 K | |||
| EBITDA | (23.14 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in Mydecine Pink Sheet
Mydecine Innovations financial ratios help investors to determine whether Mydecine Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mydecine with respect to the benefits of owning Mydecine Innovations security.